PT - JOURNAL ARTICLE AU - Zurita-Cruz, Nelly Daniela AU - Martín-Ramírez, Alexandra AU - Rodríguez-Serrano, Diego Aníbal AU - González-Álvaro, Isidoro AU - Roy-Vallejo, Emilia AU - De la Cámara, Rafael AU - García-Rodrigo, Leticia Fontán AU - Domingo, Laura Cardeñoso TI - Usefulness of real-time RT-PCR to understand the kinetics of SARS-CoV-2 in blood: a prospective study AID - 10.1101/2022.03.07.22271764 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.07.22271764 4099 - http://medrxiv.org/content/early/2022/03/08/2022.03.07.22271764.short 4100 - http://medrxiv.org/content/early/2022/03/08/2022.03.07.22271764.full AB - Background SARS-CoV-2 viral load and kinetics assessed in serial blood samples from hospitalised COVID-19 patients by RT-PCR are poorly understood.Methods We conducted an observational, prospective case series study in hospitalised COVID-19 patients. Clinical outcome data (Intensive Care Unit admission and mortality) were collected from all patients until discharge. Viremia was determined longitudinally during hospitalisation, in plasma and serum samples using two commercial and standardised RT-PCR techniques approved for use in diagnosis of SARS-CoV-2. Viral load (copies/mL and log10) was determined with quantitative TaqPath™COVID-19 test.Results SARS-CoV-2 viremia was studied in 57 hospitalised COVID-19 patients. Persistent viremia (PV) was defined as two or more quantifiable viral loads detected in blood samples (plasma/serum) during hospitalisation. PV was detected in 16 (28%) patients. All of them, except for one who rapidly progressed to death, cleared viremia during hospitalisation. Poor clinical outcome occurred in 62.5% of patients with PV, while none of the negative patients or those with sporadic viremia presented this outcome (p<0.0001). Viral load was significantly higher in patients with PV than in those with Sporadic Viremia (p<0.05). Patients presented PV for a short period of time: median time from admission was 5 days (Range=2-12) and 4.5 days (Range=2-8) for plasma and serum samples, respectively. Similar results were obtained with all RT-PCR assays for both types of samples.Conclusions Detection of persistent SARS-CoV-2 viremia, by real time RT-PCR, expressed as viral load over time, could allow identifying hospitalised COVID-19 patients at risk of poor clinical outcome.HighlightsCommercial RT-PCR techniques could be used to monitor SARS-CoV-2 viremia kinetics.SARS-CoV-2 persistent viremia is related with poor outcome in COVID-19 patient.SARS-Cov-2 viremia kinetics could be used as a biomarker of poor prognosis.Plasma samples are the best choice for analysis of SARS-CoV-2 viremia kinetics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The work of E. Roy-Vallejo has been funded by a Rio-Hortega grant CM19/00149 from the Ministerio de Economia y Competitividad (Instituto de Salud Carlos III) and co-funded by The European Regional Development Fund (ERDF) "A way to make Europe"Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients gave their informed consent, and the research protocol was approved by the Institutional Ethics Review Board from Hospital Universitario de La Princesa(register number 4267).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors